This is the authors' abstract. We don't add key points for this paper.
The concept of drug-likeness distills the physicochemical properties of small-molecule drugs to a set of rules. Macrocyclic drugs are known to break these rules. A structure-based macrocyclization strategy was applied to design new hepatitis C virus NS5B inhibitors with improved pharmacokinetic properties, exemplifying a rational strategy for overcoming the confines of standard “drug-like chemical space”.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cummings et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: